World news – Earnings per share of $ 0.61 for Beacon Roofing Supply, Inc. (NASDAQ: BECN) expected this quarter


Sign up for MarketBeat All Access to get access to all of MarketBeat’s research:

Stock analysts expect Beacon Roofing Supply, Inc. (NASDAQ: BECN) to generate earnings per quarter for the current quarter Stock (EPS) will announce $ 0.61, Zacks reports. Seven analysts have released estimates for Beacon Roofing Supply’s earnings, with the lowest EPS estimate being $ 0.48 and the highest being $ 0.66. Beacon Roofing Supply reported earnings per share of $ 0.32 for the same quarter last year, representing a positive growth rate of 90.6% year over year. The company is expected to release its next earnings report on Monday, February 1st.

On average, analysts expect Beacon Roofing Supply to post annual earnings of $ 2.97 per share for the current fiscal year, with EPS- Estimates range between $ 2.72 and $ 3.56. For the next year, analysts are forecasting earnings of $ 3.39 per share, with EPS estimates ranging between $ 3.10 and $ 4.03. Zacks’ EPS averages are based on a survey of analysts involved in Beacon Roofing Supply.

Beacon Roofing Supply (NASDAQ: BECN) last released its quarterly results on Wednesday, November 18th. The company reported earnings of $ 1.32 per share for the quarter, beating analysts’ consensus estimate of $ 0.99 by $ 0.33. The company had revenue of $ 2.02 billion for the quarter, compared to the consensus estimate of $ 2.02 billion. Beacon Roofing Supply achieved a positive return on equity of 10.89% and a negative net margin of 1.16%. For the same quarter last year, the company had earnings per share of $ 1.04.

Recently, several equity analysts rated the BECN share. ValuEngine downgraded the Beacon Roofing Supply from a « sell » rating to a « strong sell » rating in a research report on Friday November 27th. Loop Capital raised its target price on Beacon Roofing Supply from $ 42.00 to $ 46.00 and rated the company a « Buy » in a report on Friday, November 20. Deutsche Bank Aktiengesellschaft raised its target price for Beacon Roofing Supply from USD 41.00 to USD 44.00 in a report on Tuesday, December 22nd. Jefferies Financial Group upgraded Beacon Roofing Supply from a « Hold » rating to a « Buy » rating in a report on Wednesday, October 14, and raised its price target for the company from $ 33.00 to $ 44.00 raised. Finally, Robert W. Baird raised his target price on Beacon Roofing Supply from $ 43.00 to $ 48.00 and rated the company as « Outperform » in a report on Friday, November 20. Three investment analysts have rated the stock with a sell rating, five with a hold rating, seven with a buy rating and one with a strong buy rating. Beacon Roofing Supply currently has a consensus rating of « Hold » and an average price target of $ 32.81 (adsbygoogle = window.adsbygoogle || []). Push ({});

NASDAQ BECN opened at $ 42.21 on Monday. The company has a market cap of $ 2.91 billion, a PE ratio of -25.58, and a beta of 1.97. The company has a leverage ratio of 1.56, a fast rate of 1.25, and a current rate of 1.82. The company’s 50-day moving average is $ 38.88 and the 200-day moving average is $ 33.21. Beacon Roofing Supply has a fifty-two week low of $ 11.66 and a fifty-two week high of $ 43.52.

Several institutional investors recently increased or decreased their stake in BECN. FMR LLC increased its stake in Beacon Roofing Supply by 48.0% in the second quarter. FMR LLC now owns 5,241,792 shares in the company valued at $ 138,226,000 after purchasing an additional 1,698,845 shares during the period. Fisher Asset Management LLC increased its stake in Beacon Roofing Supply by 41.7% in the third quarter. Fisher Asset Management LLC now owns 1,590,543 shares in the company valued at $ 49,418,000, after acquiring an additional 467,755 shares last quarter. WCM Investment Management LLC increased its stake in Beacon Roofing Supply by 6.5% in the second quarter. WCM Investment Management LLC now owns 609,175 shares in the company valued at $ 16,064,000 after purchasing an additional 37,330 shares in the last quarter. Bank of America Corp. DE increased its stake in Beacon Roofing Supply by 3.4% in the second quarter. Bank of America Corp DE now owns 483,731 shares in the company valued at $ 12,757,000 after purchasing an additional 15,806 shares during the reporting period. Finally, Granite Investment Partners LLC acquired a new position in Beacon Roofing Supply for $ 13,967,000 in the third quarter.

Beacon Roofing Supply, Inc, together with its subsidiaries, distributes residential and non-residential roofing materials and ancillary construction products to contractors, builders, builders and retailers. The company’s residential roofing products include asphalt shingles, synthetic slates and bricks, clay and concrete tiles, slate, nail base insulation, metal roofs, felts, synthetic underlays, wood shingles and shakes, nails and fasteners, metal edging and siding, precast ledges, ridges and Reveal openings as well as solar systems.

This instant messaging alert was generated using narrative science technology and financial data from MarketBeat to give readers the fastest, most accurate coverage possible. This story has been reviewed by the editorial staff of MarketBeat prior to publication. Please send questions or comments about this story to [email protected]

October 2nd, 2020 may not count as a « Where were you when? » But when the news came that the President of the United States and First Lady tested positive for the novel coronavirus, it certainly felt like we were living in a historic moment (as if we weren’t already).

In the days that followed, several biotech and pharmaceutical companies made headlines. These weren’t the vaccine stocks investors remembered, however. These were companies leading the race for antiviral therapeutics.

And with a very well known proof of concept, therapeutics may have had their moment. It is far too early to tell whether these drugs really hold the answer. However, from the start of the pandemic, there was a feeling that therapeutics could be the ultimate solution for neutralizing the most serious effects of the new coronavirus.

As might be expected, there is no shortage of enterprise in the therapeutic discussion. In this special presentation we introduce seven companies that you should pay special attention to. If therapeutics are one step ahead of a vaccine, these stocks are likely to see strong upside moves.

Fill out the form below to receive the latest headlines and analyst recommendations for your stocks with our free daily email newsletter:

Sign up to MarketBeat All Access to access the full Get Research From MarketBeat:

View the latest news, buy / sell ratings, SEC filings, and insider deals for your stocks. Compare your portfolio performance against leading indices and get personalized stock ideas based on your portfolio.

Get stock ideas daily with the best Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. See what stocks are up to date on social media with MarketBeat’s Trending Stock Report.

Identify stocks that match your criteria with seven unique stock screeners. See what’s happening in the market with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.

Looking for new ideas for stocks? Would you like to see which stocks are moving? View our full range of financial calendars and market data tables for free.

Receive free world class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

MarketBeat enables individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, company buybacks, dividends, earnings, business reports, financial data, insider trading, IPOs, SEC filings, or stock splits, MarketBeat has the objective information you need to analyze stocks. Learn more.

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St # 105, Sioux Falls, SD 57103 | [Email protected] | (844) 978-6257
MarketBeat does not provide financial advice or make recommendations or offers to buy stocks or sell any securities. Learn more.
Don’t sell my information

© 2021 The market data provided will be delayed by at least 10 minutes and hosted by Barchart Solutions. Basic corporate data from Morningstar and Zacks Investment Research. The information is provided « as is » and for informational purposes only, not for commercial or advisory purposes, and is delayed. Please see the disclaimer for all delays and terms of use for exchanges.

Enter your email address below to receive a quick daily summary of upgrades, downgrades and new coverage from Analysts with’s FREE daily email newsletter.



Donnez votre point de vue et aboonez-vous!


Votre point de vue compte, donnez votre avis

[maxbutton id= »1″]